Literature DB >> 14659147

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Keith N Ogston1, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys.   

Abstract

The clinical and complete pathological response of a primary breast cancer to chemotherapy has been shown to be an important prognostic for survival. However, the majority of patients do not experience a complete pathological response to primary chemotherapy and the significance of lesser degrees of histological response is uncertain and the prognostic significance is unknown. The purpose of this study was to evaluate a new histological grading system to assess response of breast cancers to primary chemotherapy and to determine if such a system has prognostic value.A consecutive series of 176 patients with large (> or =4cm) and locally advanced breast cancers were treated with multimodality therapy comprising primary chemotherapy, surgery, radiotherapy and tamoxifen. All underwent assessment of the primary breast tumour before and after completion of chemotherapy. Residual tumour was excised after completion of chemotherapy (mastectomy or wide local excision with axillary surgery). The removed tissue was assessed and response to chemotherapy graded using a five-point histological grading system based with the fundamental feature being a reduction in tumour cellularity; comparison being made with a pre-treatment core biopsy. All patients were followed up for 5 years or more. Pathological responses were compared to 5 year overall survival and disease-free survival using log rank tests. The overall 5-year survival for all patients was 71%, and 5 year disease free interval was 60%. There was a significant correlation between pathological response using this new grading system and both overall survival (P=0.02) and disease-free interval (P=0.04). In a multivariate analysis of known prognostic factors, the Miller/Payne grading system was an independent predictor of overall patient survival. This grading system, which assesses the histological response to primary chemotherapy, can predict overall survival and disease-free interval in patients with large and locally advanced breast cancers treated with such therapy. The relationship of degree of histological response to overall and disease-free survival has been shown in univariate and multivariate analyses and could potentially have an important role in the clinical management of patients with locally advanced breast cancer undergoing primary chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659147     DOI: 10.1016/s0960-9776(03)00106-1

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  239 in total

1.  Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Irma Soldevilla-Gallardo; Sevastian S Medina-Ornelas; Cynthia Villarreal-Garza; Enrique Bargalló-Rocha; Claudia Hs Caro-Sánchez; Rodrigo Hernández-Ramírez; Enrique Estrada-Lobato
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients?

Authors:  Laura Evangelista; Domenico Rubello; Giorgio Saladini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03       Impact factor: 9.236

3.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 4.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

5.  Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

Authors:  David Groheux; Sylvie Giacchetti; Marc Espié; Domenico Rubello; Jean-luc Moretti; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03       Impact factor: 9.236

6.  Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo.

Authors:  Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

7.  Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.

Authors:  Min Ying; Yingjian He; Meng Qi; Bin Dong; Aiping Lu; Jinfeng Li; Yuntao Xie; Tianfeng Wang; Benyao Lin; Tao Ouyang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

8.  Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.

Authors:  Bruce J Tromberg; Zheng Zhang; Anaïs Leproux; Thomas D O'Sullivan; Albert E Cerussi; Philip M Carpenter; Rita S Mehta; Darren Roblyer; Wei Yang; Keith D Paulsen; Brian W Pogue; Shudong Jiang; Peter A Kaufman; Arjun G Yodh; So Hyun Chung; Mitchell Schnall; Bradley S Snyder; Nola Hylton; David A Boas; Stefan A Carp; Steven J Isakoff; David Mankoff
Journal:  Cancer Res       Date:  2016-08-15       Impact factor: 12.701

9.  Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging.

Authors:  Hamed Vavadi; Atahar Mostafa; Feifei Zhou; K M Shihab Uddin; Murad Althobaiti; Chen Xu; Rajeev Bansal; Foluso Ademuyiwa; Steven Poplack; Quing Zhu
Journal:  J Biomed Opt       Date:  2018-10       Impact factor: 3.170

10.  Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Authors:  Joanna Szkandera; Gudrun Absenger; Nadia Dandachi; Peter Regitnig; Sigurd Lax; Michael Stotz; Hellmut Samonigg; Wilfried Renner; Armin Gerger
Journal:  Mol Genet Genomics       Date:  2012-08-18       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.